US2020231703A1PendingUtilityA1

Treatment of ocular disease

68
Assignee: AERPIO PHARMACEUTICALS INCPriority: Oct 13, 2011Filed: Jan 24, 2020Published: Jul 23, 2020
Est. expiryOct 13, 2031(~5.3 yrs left)· nominal 20-yr term from priority
Inventors:Kevin PetersRobert Shalwitz
A61K 2039/505A61P 27/02A61P 31/04C07K 2317/75A61P 7/10A61P 27/06A61K 2039/54A61P 35/00A61P 43/00C07K 16/40C07K 2317/76A61P 9/10
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A pharmaceutical composition comprising a therapeutically-effective amount of a multi-specific antibody, wherein the multi-specific antibody binds to a human protein tyrosine phosphatase beta-extracellular domain (HPTPβ-ECD) in a subject, and wherein the therapeutically-effective amount of the multi-specific antibody is from about 0.01 mg/kg to about 500 mg/kg by weight of the subject. 
     
     
         22 . The pharmaceutical composition of  claim 21 , wherein the multispecific antibody binds to an FN3 repeat in the HPTPβ-ECD. 
     
     
         23 . The pharmaceutical composition of  claim 21 , wherein the multispecific antibody binds to a first FN3 repeat in the HPTPβ-ECD. 
     
     
         24 . The pharmaceutical composition of  claim 21 , wherein the multispecific antibody inhibits HPTPβ. 
     
     
         25 . The pharmaceutical composition of  claim 21 , wherein the multispecific antibody binds to SEQ ID NO.: 4. 
     
     
         25 . The pharmaceutical composition of  claim 21 , wherein the pharmaceutical composition is a solution, and the solution has a pH of from about 7 to about 7.5. 
     
     
         26 . The pharmaceutical composition of  claim 21 , wherein the multi-specific antibody is a bispecific antibody. 
     
     
         27 . The pharmaceutical composition of  claim 21 , wherein the therapeutically-effective amount of the multi-specific antibody is from about 0.1 mg/kg to about 50 mg/kg. 
     
     
         28 . The pharmaceutical composition of  claim 21 , further comprising a carrier. 
     
     
         29 . A method for treating an ocular condition in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition, wherein the pharmaceutical composition comprises a therapeutically-effective amount of a multi-specific antibody, wherein the multi-specific antibody binds to a human protein tyrosine phosphatase beta-extracellular domain (HPTPβ-ECD) in a subject, and wherein the therapeutically-effective amount of the multi-specific antibody is from about 0.01 mg/kg to about 500 mg/kg by weight of the subject. 
     
     
         30 . The method of  claim 29 , wherein the multispecific antibody binds to an FN3 repeat in the HPTPβ-ECD. 
     
     
         31 . The method of  claim 29 , wherein the multispecific antibody binds to a first FN3 repeat in the HPTPβ-ECD. 
     
     
         32 . The method of  claim 29 , wherein the multispecific antibody inhibits HPTPβ. 
     
     
         33 . The method of  claim 29 , wherein the multispecific antibody binds to SEQ ID NO.: 4. 
     
     
         34 . The method of  claim 29 , wherein the pharmaceutical composition is a solution, and the solution has a pH of from about 7 to about 7.5. 
     
     
         35 . The method of  claim 29 , wherein the multi-specific antibody is a bispecific antibody. 
     
     
         36 . The method of  claim 29 , wherein the therapeutically-effective amount of the multi-specific antibody is from about 0.1 mg/kg to about 50 mg/kg. 
     
     
         37 . The method of  claim 29 , wherein the pharmaceutical composition is administered by intraocular injection. 
     
     
         38 . The method of  claim 29 , wherein the pharmaceutical composition is administered by subcutaneous injection. 
     
     
         39 . The method of  claim 29 , wherein the pharmaceutical composition is administered by intravenous injection. 
     
     
         40 . The method of  claim 29 , wherein the subject is human. 
     
     
         41 . The method of  claim 29 , wherein the pharmaceutical composition further comprises a carrier.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.